home / stock / bivi / bivi news

BIVI News and Press, BioVie Inc. From 06/23/22

Stock Information
Company Name: BioVie Inc.
Stock Symbol: BIVI
Market: NASDAQ
Website: biovieinc.com
Menu
BIVI BIVI Quote BIVI Short BIVI News BIVI Articles BIVI Message Board
Get BIVI Alerts

News, Short Squeeze, Breakout and More Instantly...
BIVI - Micro-cap BioVie rises after getting back patent protection for its ascites treatment

BioVie (NASDAQ:BIVI) on Thursday said it had won a patent for its ascites medicine BIV201 which was expected to cover treatment with it in the U.S. until 2036. BIVI stock gained 7.1% to $1.80 in premarket trading. The U.S. Patent & Trademark Office (USPTO) issued BIVI ...
BIVI - BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

CARSON CITY, Nev., June 23, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced t...

BIVI - BioVie: Four Potential Catalysts Around The Corner

With four readouts in Parkinson’s disease, refractory ascites and Alzheimer’s disease, the coming year may be defining for BioVie. Topline results of the Phase 2a trial in Parkinson’s disease should in principle be released in the coming months. The potential ...

BIVI - BioVie to Participate at the B. Riley Securities' Neuro & Ophthalmology Conference

CARSON CITY, Nev., April 25, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative dis...
BIVI - BioVie, Progenity top healthcare gainers; Nymox, HTG Molecular lead losers' pack

Gainers: BioVie (BIVI) +16%. Progenity (PROG) +16%. Kezar Life Sciences (KZR) +14%. Codiak BioSciences (CDAK) +13%. Ensysce Biosciences (ENSC) +10%. Losers: Nymox Pharmaceutical (NYMX) -29%. HTG Molecular Diagnostics (HTGM) -14%. Zhongchao (ZC...

BIVI - BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that an interview with Presi...

BIVI - BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference

RENO, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders,...
BIVI - BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson's Disease

RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders today ...

BIVI - BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event

RENO, Nev., Dec. 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, ...

BIVI - BioVie Announces Partnership with the American Liver Foundation

RENO, Nev., Dec. 09, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, ...
Previous 10 Next 10